Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00667641 | Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | completed | Phase 1 | 16 | University of Medicine and Dentistry of New JerseyOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00700167 | Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy | completed | Phase 1 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 20, 2011 | clinicaltrials |
| NCT00680589 | Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 28, 2011 | clinicaltrials |
| NCT00045357 | Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00327600 | Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 68 | AmpliMed CorporationINDUSTRY | 1 | Sep 15, 2010 | clinicaltrials |
| NCT00609011 | Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma | completed | Phase 1 / Phase 2 | 22 | Myrexis Inc.INDUSTRY | 1 | Aug 23, 2010 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
| NCT00688090 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. | completed | Phase 1 | 19 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
| NCT00002786 | Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00045149 | Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 | — | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2010 | clinicaltrials |
| NCT00197912 | Dendritic Cell Based Therapy of Malignant Melanoma | completed | Phase 1 / Phase 2 | 25 | Herlev HospitalOTHER | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00729950 | Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 92 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00034554 | Study of gp75 Vaccine in Patients With Stage III and IV Melanoma | completed | Phase 1 | 31 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00116597 | Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 2, 2009 | clinicaltrials |
| NCT00243529 | Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients | completed | Phase 1 / Phase 2 | 64 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2009 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00379132 | 131-I-TM-601 Study in Adults With Solid Tumors | completed | Phase 1 | 60 | TransMolecularINDUSTRY | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00095108 | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | completed | Phase 1 | 43 | ZymoGeneticsINDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00243594 | Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection | completed | Phase 1 / Phase 2 | 40 | Radboud University Medical CenterOTHER | 1 | Feb 19, 2009 | clinicaltrials |
| NCT00847106 | Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 15 | Radboud University Medical CenterOTHER | 0 | Feb 19, 2009 | clinicaltrials |
| NCT00091689 | Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions | completed | Phase 1 | — | PfizerINDUSTRY | 1 | Oct 27, 2008 | clinicaltrials |
| NCT00001439 | A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant | completed | Phase 1 | 255 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001577 | Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001683 | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00559026 | Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients(DTIC-melvacc) | completed | Phase 1 | 10 | Istituto Superiore di SanitàOTHER | 1 | Nov 16, 2007 | clinicaltrials |
| NCT00306514 | Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients | completed | Phase 1 / Phase 2 | — | Cytos Biotechnology AGINDUSTRY | 1 | Sep 20, 2007 | clinicaltrials |
| NCT00306566 | Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients | completed | Phase 1 / Phase 2 | — | Cytos Biotechnology AGINDUSTRY | 1 | Sep 20, 2007 | clinicaltrials |
| NCT00219843 | Intralesional PV-10 Chemoablation of Metastatic Melanoma | completed | Phase 1 | 20 | Provectus PharmaceuticalsINDUSTRY | 1 | Aug 23, 2007 | clinicaltrials |
| NCT00515983 | Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells | completed | Phase 1 | 16 | José Mordoh, M.D., Ph.D.OTHER | 1 | Aug 14, 2007 | clinicaltrials |
| NCT00204607 | Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | University Hospital TuebingenOTHER | 1 | Apr 19, 2007 | clinicaltrials |
| NCT00041808 | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | completed | Phase 1 / Phase 2 | 20 | FeRxINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated May 10, 2011source: clinicaltrials